Birchtech Corp. (NYSE American: BCHT) is a small, single-segment specialty activated carbon technology company that earns the bulk of its revenue from selling mercury sorbents to U.S. coal-fired power plants, while positioning a developing water purification platform aimed at PFAS and PFOS as a forward growth lever. The company trades on NYSE American under the ticker BCHT at a recent price of $1.40, leaving a market capitalization of roughly $36.8 million on 26.3 million shares outstanding, a price that has collapsed from a 52-week high of $4.75 set in December 2025 and sits close to the 52-week low of $1.29 touched in mid-August 2026.
The most recent reported quarter, the three months ended June 30, 2026, produced total revenue of $3.79 million, up 16.5% from $3.25 million in the prior-year quarter, while gross profit improved to $1.03 million from $0.97 million. The growth story is misleading at the operating-line level because operating loss widened to $1.62 million from $1.19 million, and a $1.25 million one-time license and settlement fee, recorded in other expense, pushed the net loss to $3.02 million, almost double the $1.54 million loss in the second quarter of 2025. First-half results reinforce the same pattern: revenue rose 24.0% to $8.03 million from $6.47 million, gross profit climbed to $2.42 million from $2.20 million, and the operating loss expanded to $2.77 million from $2.53 million, with a $4.36 million net loss against $3.22 million in the year-ago half.
The single most consequential change in the Birchtech story during the past six months is balance-sheet repair. Management had flagged going-concern doubt in the prior annual filing, but the company completed an underwritten public offering of common stock on February 27, 2026 and again on March 17, 2026 after partial exercise of the underwriters' overallotment option, generating aggregate gross proceeds of $16.4 million. Cash stood at $11.84 million at June 30, 2026, up from $2.25 million at year-end 2025, and stockholders' equity swung from a $1.71 million deficit at December 31, 2025 to an $8.15 million surplus at the end of the most recent quarter. Net cash used in operations widened to $4.997 million in the first half from $1.986 million a year earlier, so the runway now exists, but the operating burn rate has not yet been curtailed.
The investment case here is binary and hinges on three things: the durability of mercury sorbent demand from the small remaining U.S. coal fleet under the post-2024 strengthened Mercury and Air Toxics Standards, the conversion of water-treatment technology from a development-stage cost center into a paying customer base, and the company's ability to monetize its patent portfolio through licensing and litigation settlements. A $1.25 million license and settlement fee recorded in the second quarter is a meaningful data point in the third lever, and management commentary within the filing signals that the company continues to view patent enforcement as a core revenue channel.
Investors should approach BCHT with awareness that the share count has expanded by 35% in twelve months (from 19.25 million weighted-average shares in the second quarter of 2025 to 26.31 million in the recent quarter), reflecting both the public offering and earlier issuances, and a July 23, 2026 stockholder vote reduced authorized shares from 150 million to 50 million, a structural change that limits the board's ability to dilute further without a fresh stockholder mandate. The current share price embeds a steep discount to book value (the $8.15 million equity book, multiplied across 26.3 million shares, implies $0.31 of book value per share, while the stock trades at $1.40), suggesting the market is pricing in continued operating losses and execution risk rather than valuing the balance sheet or the patent portfolio.